Stock Watch: Amphastar’s Turn Away From Generics
Specialty Pharma Treads A Precarious Path Between Pharma And Generics
Executive Summary
Amphastar’s 2020 financial results included its best ever quarter and a different revenue pattern from most pharma and generic companies. Its evolving product mix and marketing campaigns were two reasons for its performance.
You may also be interested in...
Stock Watch: Defeat Is The Mother Of Reinvention
Companies that are successful do not need to change their name, therapeutic area or product focus.
Stock Watch: The Pandemic – Where Generics Failed To Reign
If demand-side pressures on the life science sector were not enough, generic price erosion, debt repayment and extended restructurings are worsening the generic pharmaceutical investment proposition.
Amphastar Has First US Glucagon Rival
Amphastar has secured the first US approval for a generic version of Eli Lilly’s glucagon emergency kit.